Second-line chemotherapy for non-small-cell lung cancer: recent data with pemetrexed |
| |
Authors: | Hanna Nasser H |
| |
Affiliation: | University of British Columbia, Division of Medical Oncology, BC Cancer Agency, Vancouver, Canada. jlaskin@bccancer.bc.ca |
| |
Abstract: | Bronchoalveolar carcinoma (BAC) is a subtype of non-small-cell lung cancer (NSCLC) with unique clinical and pathologic characteristics. The most recent classification system defines BAC as a primary lung cancer that tends to be peripheral and grow in a lepedic fashion along the alveolar septae without parenchymal invasion. Most of the clinical information on BAC comes from retrospective institutional reviews; however, recent studies have focused more specifically on BAC. In particular, clinical trials of molecular-targeted anticancer therapies against the epidermal growth factor receptor have led to a deeper understanding of the distinct features of this cancer and suggest that BAC may require a therapeutic paradigm different from that of other NSCLCs. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|